A global view of hepatocellular carcinoma: trends, risk, prevention and management

Ju Dong Yang, Pierre Hainaut, Gregory James Gores, Amina Amadou, Amelie Plymoth, Lewis Rowland Roberts

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.

Original languageEnglish (US)
JournalNature Reviews Gastroenterology and Hepatology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Risk Management
Hepatocellular Carcinoma
Liver Diseases
Therapeutics
Neoplasms
Aflatoxins
Metabolic Diseases
Chronic Hepatitis B
Hepatitis C
Liver Transplantation
Hepatitis
Alcoholism
Comorbidity
Phosphotransferases
Catheters

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

A global view of hepatocellular carcinoma : trends, risk, prevention and management. / Yang, Ju Dong; Hainaut, Pierre; Gores, Gregory James; Amadou, Amina; Plymoth, Amelie; Roberts, Lewis Rowland.

In: Nature Reviews Gastroenterology and Hepatology, 01.01.2019.

Research output: Contribution to journalReview article

@article{a82e0c6ac6e44ce6b2a45078e4285a45,
title = "A global view of hepatocellular carcinoma: trends, risk, prevention and management",
abstract = "Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.",
author = "Yang, {Ju Dong} and Pierre Hainaut and Gores, {Gregory James} and Amina Amadou and Amelie Plymoth and Roberts, {Lewis Rowland}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41575-019-0186-y",
language = "English (US)",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A global view of hepatocellular carcinoma

T2 - trends, risk, prevention and management

AU - Yang, Ju Dong

AU - Hainaut, Pierre

AU - Gores, Gregory James

AU - Amadou, Amina

AU - Plymoth, Amelie

AU - Roberts, Lewis Rowland

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.

AB - Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.

UR - http://www.scopus.com/inward/record.url?scp=85071507968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071507968&partnerID=8YFLogxK

U2 - 10.1038/s41575-019-0186-y

DO - 10.1038/s41575-019-0186-y

M3 - Review article

C2 - 31439937

AN - SCOPUS:85071507968

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

ER -